For research use only
| Cat No. | ABC-TC0477 |
| Product Type | Human Skin Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | JL1 |
Established from the untreated malignant epithelioid mesothelioma of the pleura of a 54-year-old man with asbestos cancer in 2003
JL‑1 is a human malignant epithelioid mesothelioma cell line established from untreated pleural tumor tissue of a 54‑year‑old male patient with asbestos‑associated mesothelioma, representing an aggressive epithelial subtype of pleural cancer. The cells exhibit adherent epithelial‑like morphology in monolayer culture, with documented STR authenticity and a spectrum of chromosomal abnormalities consistent with malignant mesothelioma cytogenetics. JL‑1 participates in oncogenomic and transcriptomic profiling studies of mesothelioma and is included in cancer cell line panels such as the Cancer Dependency Map (DepMap) for in vitro modeling of pleural tumor biology. Evidence supports its use in proliferation and drug response assays, but specific in vivo metastatic behavior is not broadly characterized. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV‑1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | JL1 |
| Species | Human |
| Cat.No | ABC-TC0477 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Skin Cancer Cell Lines |
JL‑1 is used as an in vitro model of human epithelioid pleural mesothelioma for studies of tumor cell proliferation, apoptosis, and migration, as well as signaling pathways associated with asbestos-induced oncogenesis. It serves in gene expression profiling, epigenetic and transcriptomic analyses, and evaluation of chemotherapeutic or targeted anticancer drug responses. JL‑1 is also applied in mechanistic studies of mesothelial cell transformation, investigation of tumor-stroma interactions, and assessment of novel molecular therapies or immunomodulatory agents in malignant mesothelioma research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
